Abemaciclib, i-aromatase inhibitor, U-Eli Lilly neNkampani, ukwelashwa kwe-endocrine, Tamoxifen, UVerzenio
I-Abemaciclib ngokwelashwa kwe-endocrine kuvunywe yi-FDA kumdlavuza webele we-HER 2 omuhle
Mashi 2023: I-Abemaciclib (Verzenio, Eli Lilly and Company) kanye nokwelashwa kwe-endocrine (tamoxifen noma i-aromatase inhibitor) kugunyazwe i-Food and Drug Administration (FDA) ukuze kusetshenziswe i-adjuvant yeziguli ezikhulile ezine-.
Izivivinyo zokwelashwa kwamaseli e-CAR T, I-glioblastoma, ukuhlolwa kwe-glioblastoma, ama-gliomas
Ucwaningo Lokuphepha Nokusebenza Kahle lwe-Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
I-American Society of Hematology, I-Carteyva, China, I-JW Therapeutics, i-relmacabtagene autoleucel
I-JW Therapeutics Yethula Idatha Yakamuva Yomtholampilo ku-Carteyva® ku-Follicular Lymphoma kanye ne-Mantle Cell Lymphoma eMhlanganweni Wonyaka wama-64 we-ASH
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
I-dMMR, I-Dostarlimab-gxly, GlaxoSmithKline, I-Jemperli
I-Dostarlimab-gxly igunyazwe yi-FDA ngomdlavuza we-endometrial we-dMMR
Feb 2023: I-Dostarlimab-gxly (i-Jemperli, i-GlaxoSmithKline LLC) yanikezwa imvume ye-FDA yokwelapha iziguli ezikhulile ezinomdlavuza ophindaphindayo noma othuthukile we-endometrial oqhubeke noma ngemva kwalokho.
Daiichi Sankyo, I-DESTINY-Breast04, I-Enhertu, fam-trastuzumab deruxtecan-nxki
I-Fam-trastuzumab deruxtecan-nxki igunyazwe yi-FDA ngomdlavuza webele we-HER2-low
Agasti 2022: Ezigulini ezikhulile ezinomdlavuza webele ongalungiseki noma one-metastatic HER2-low (IHC 1+ noma IHC 2+/ISH) ezithole ukwelashwa ngamakhemikhali kwangaphambilini esimweni se-metastatic noma ezihlangabezane nokuvela kwesifo phakathi noma phakathi nezinyanga eziyisithupha.
I-AstraZeneca Pharmaceuticals, I-BRCA, gBRCAm, I-Lynparza, i-olaparib, I-OlympiA
I-Olaparib igunyazelwe ukwelashwa kwe-adjuvant yomdlavuza webele wangaphambi kwesikhathi osengozini enkulu
Mashi 2022: I-Food and Drug Administration igunyaze i-olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) yokwelapha i-adjuvant yeziguli ezikhulile ezinegciwane elisusayo noma elisolwa ngokususa i-BRCA-mutated (gBRCAm) h.
I-Atezolizumab, Bevacizumab, nivolumab, I-Regorafenib, I-Stivarga, I-Tecentriq
Izidakamizwa ezigunyazwe ukwelapha umdlavuza wesibindi
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, IKRAS G12C, I-Lumakras, I-NSCLC, sotorasib
I-FDA igunyaze ukwelashwa okuhlosiwe kokuqala kokuguqulwa komdlavuza wamaphaphu okwakucatshangwa ukuthi awuzweli emishanguzweni.
Agasti 20, 2021: Muva nje ngoMeyi, i-2021 Lumakras (sotorasib) yamukelwa yi-US Food and Drug Administration njengokwelashwa kokuqala kweziguli ezindala ezinomdlavuza ongewona omncane wamangqamuzana wamaphaphu asebenze okungenani uhlelo olulodwa lwangaphambilini ..
KEYTRUDA, Merck, I-NCT02362594, I-Pembrolizumab, KHUMBULA, USFDA
I-Pembrolizumab yamukelwa yi-FDA ekwelashweni nge-adjuvant kwe-melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
I-Ablynx, ADAMUTS13, I-CABLIVI, i-caplacizumab-yhdp, FDA, ukwelashwa kokuzivikela komzimba, USFDA
ICaplacizumab-yhdp ivunyelwe yi-FDA
NgoFebhuwari 6, 2019, ngokuhlangana nokushintshaniswa kwe-plasma kanye nokwelashwa kwe-immunosuppressive, i-Food and Drug Administration igunyaze i-caplacizumab-yhdp (CABLIVI, Ablynx NV) yeziguli ezindala ezine-thrombotic cystopeni.